Literature DB >> 33500417

Onchocerca volvulus bivalent subunit vaccine induces protective immunity in genetically diverse collaborative cross recombinant inbred intercross mice.

Nathan M Ryan1, Jessica A Hess1, Fernando Pardo-Manuel de Villena2, Benjamin E Leiby3, Ayako Shimada3, Lei Yu4, Amir Yarmahmoodi4, Nikolai Petrovsky5, Bin Zhan6,7, Maria Elena Bottazzi6,7, Benjamin L Makepeace8, Sara Lustigman9, David Abraham10.   

Abstract

This study tests the hypothesis that an Onchocerca volvulus vaccine, consisting of two recombinant antigens (Ov-103 and Ov-RAL-2) formulated with the combination-adjuvant Advax-2, can induce protective immunity in genetically diverse Collaborative Cross recombinant inbred intercross mice (CC-RIX). CC-RIX lines were immunized with the O. volvulus vaccine and challenged with third-stage larvae. Equal and significant reductions in parasite survival were observed in 7 of 8 CC-RIX lines. Innate protective immunity was seen in the single CC-RIX line that did not demonstrate protective adaptive immunity. Analysis of a wide array of immune factors showed that each line of mice have a unique set of immune responses to vaccination and challenge suggesting that the vaccine is polyfunctional, inducing different equally-protective sets of immune responses based on the genetic background of the immunized host. Vaccine efficacy in genetically diverse mice suggests that it will also be effective in genetically complex human populations.

Entities:  

Year:  2021        PMID: 33500417      PMCID: PMC7838260          DOI: 10.1038/s41541-020-00276-2

Source DB:  PubMed          Journal:  NPJ Vaccines        ISSN: 2059-0105            Impact factor:   7.344


  63 in total

1.  In vitro activity of antimicrobial agents against the endosymbiont Wolbachia pipientis.

Authors:  P G Hermans; C A Hart; A J Trees
Journal:  J Antimicrob Chemother       Date:  2001-05       Impact factor: 5.790

2.  Onchocerciasis and its control. Report of a WHO Expert Committee on Onchocerciasis Control.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1995

Review 3.  The collaborative cross: a recombinant inbred mouse population for the systems genetic era.

Authors:  David W Threadgill; Darla R Miller; Gary A Churchill; Fernando Pardo-Manuel de Villena
Journal:  ILAR J       Date:  2011

4.  The case for vaccine development in the strategy to eradicate river blindness (onchocerciasis) from Africa.

Authors:  Benjamin L Makepeace; Simon A Babayan; Sara Lustigman; David W Taylor
Journal:  Expert Rev Vaccines       Date:  2015-06-19       Impact factor: 5.217

5.  Brugia malayi: effects of antibacterial agents on larval viability and development in vitro.

Authors:  Ramakrishna U Rao; Hanaa Moussa; Gary J Weil
Journal:  Exp Parasitol       Date:  2002-05       Impact factor: 2.011

6.  HLA-D alleles associated with generalized disease, localized disease, and putative immunity in Onchocerca volvulus infection.

Authors:  C G Meyer; M Gallin; K D Erttmann; N Brattig; L Schnittger; A Gelhaus; E Tannich; A B Begovich; H A Erlich; R D Horstmann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

7.  Human Onchocerciasis: Modelling the Potential Long-term Consequences of a Vaccination Programme.

Authors:  Hugo C Turner; Martin Walker; Sara Lustigman; David W Taylor; María-Gloria Basáñez
Journal:  PLoS Negl Trop Dis       Date:  2015-07-17

8.  Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses.

Authors:  Denis Gaucher; René Therrien; Nadia Kettaf; Bastian R Angermann; Geneviève Boucher; Abdelali Filali-Mouhim; Janice M Moser; Riyaz S Mehta; Donald R Drake; Erika Castro; Rama Akondy; Aline Rinfret; Bader Yassine-Diab; Elias A Said; Younes Chouikh; Mark J Cameron; Robert Clum; David Kelvin; Roland Somogyi; Larry D Greller; Robert S Balderas; Peter Wilkinson; Giuseppe Pantaleo; Jim Tartaglia; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  J Exp Med       Date:  2008-12-01       Impact factor: 14.307

9.  Genetic control of the antibody response. I. Demonstration of determinant-specific differences in response to synthetic polypeptide antigens in two strains of inbred mice.

Authors:  H O McDevitt; M Sela
Journal:  J Exp Med       Date:  1965-09-01       Impact factor: 14.307

10.  Vaccination of Gerbils with Bm-103 and Bm-RAL-2 Concurrently or as a Fusion Protein Confers Consistent and Improved Protection against Brugia malayi Infection.

Authors:  Sridhar Arumugam; Junfei Wei; Zhuyun Liu; David Abraham; Aaron Bell; Maria Elena Bottazzi; Peter J Hotez; Bin Zhan; Sara Lustigman; Thomas R Klei
Journal:  PLoS Negl Trop Dis       Date:  2016-04-05
View more
  4 in total

1.  Co-Administration of Adjuvanted Recombinant Ov-103 and Ov-RAL-2 Vaccines Confer Protection against Natural Challenge in A Bovine Onchocerca ochengi Infection Model of Human Onchocerciasis.

Authors:  Lisa Luu; Germanus S Bah; Ndode Herman Okah-Nnane; Catherine S Hartley; Alexandra F Glover; Tessa R Walsh; Lu-Yun Lian; Bin Zhan; Maria Elena Bottazzi; David Abraham; Nikolai Petrovsky; Nicolas Bayang; Bernard Tangwa; Rene Billingwe Ayiseh; Glory Enjong Mbah; David D Ekale; Vincent N Tanya; Sara Lustigman; Benjamin L Makepeace; John Graham-Brown
Journal:  Vaccines (Basel)       Date:  2022-05-27

Review 2.  Worms and bugs of the gut: the search for diagnostic signatures using barcoding, and metagenomics-metabolomics.

Authors:  Marina Papaiakovou; D Timothy J Littlewood; Stephen R Doyle; Robin B Gasser; Cinzia Cantacessi
Journal:  Parasit Vectors       Date:  2022-04-01       Impact factor: 3.876

Review 3.  Advancing a Human Onchocerciasis Vaccine From Antigen Discovery to Efficacy Studies Against Natural Infection of Cattle With Onchocerca ochengi.

Authors:  Bin Zhan; Maria Elena Bottazzi; Peter J Hotez; Sara Lustigman
Journal:  Front Cell Infect Microbiol       Date:  2022-04-04       Impact factor: 6.073

Review 4.  Predictive Markers of Immunogenicity and Efficacy for Human Vaccines.

Authors:  Matthieu Van Tilbeurgh; Katia Lemdani; Anne-Sophie Beignon; Catherine Chapon; Nicolas Tchitchek; Lina Cheraitia; Ernesto Marcos Lopez; Quentin Pascal; Roger Le Grand; Pauline Maisonnasse; Caroline Manet
Journal:  Vaccines (Basel)       Date:  2021-06-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.